4d2p: Difference between revisions
m Protected "4d2p" [edit=sysop:move=sysop] |
No edit summary |
||
Line 1: | Line 1: | ||
''' | ==Structure of MELK in complex with inhibitors== | ||
<StructureSection load='4d2p' size='340' side='right' caption='[[4d2p]], [[Resolution|resolution]] 2.55Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4d2p]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D2P OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4D2P FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6Z7:7-({4-[(3-HYDROXY-5-METHOXYPHENYL)AMINO]BENZOYL}AMINO)-1,2,3,4-TETRAHYDROISOQUINOLINIUM'>6Z7</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4d2t|4d2t]], [[4d2v|4d2v]], [[4d2w|4d2w]]</td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4d2p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d2p OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4d2p RCSB], [http://www.ebi.ac.uk/pdbsum/4d2p PDBsum]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[[http://www.uniprot.org/uniprot/MELK_HUMAN MELK_HUMAN]] Note=Defects in MELK are associated with some cancers, such as brain or breast cancers. Expression is dramatically increased in aggressive undifferentiated tumors, correlating with poor patient outcome in breast and brain cancers, suggesting a role in tumor-initiating cells and proliferation via its function in cell proliferation regulation. | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/MELK_HUMAN MELK_HUMAN]] Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis.<ref>PMID:11802789</ref> <ref>PMID:12400006</ref> <ref>PMID:14699119</ref> <ref>PMID:15908796</ref> <ref>PMID:16216881</ref> <ref>PMID:17280616</ref> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Non-specific serine/threonine protein kinase]] | |||
[[Category: Beke, L.]] | |||
[[Category: Berdini, V.]] | |||
[[Category: Bonnet, P.]] | |||
[[Category: Brehmer, D.]] | |||
[[Category: Coyle, J E.]] | |||
[[Category: Day, P J.]] | |||
[[Category: Frederickson, M.]] | |||
[[Category: Freyne, E J.E.]] | |||
[[Category: Gilissen, R A.H J.]] | |||
[[Category: Hamlett, C C.F.]] | |||
[[Category: Howard, S.]] | |||
[[Category: Johnson, C N.]] | |||
[[Category: Linders, J T.M.]] | |||
[[Category: McMenamin, R.]] | |||
[[Category: Meerpoel, L.]] | |||
[[Category: Patel, S.]] | |||
[[Category: Rees, D C.]] | |||
[[Category: Sharff, A.]] | |||
[[Category: Sommen, F.]] | |||
[[Category: Wu, T.]] | |||
[[Category: Fragment sterbased drug design]] | |||
[[Category: Kinase]] | |||
[[Category: Transferase]] |
Revision as of 10:47, 8 October 2014
Structure of MELK in complex with inhibitorsStructure of MELK in complex with inhibitors
Structural highlights
Disease[MELK_HUMAN] Note=Defects in MELK are associated with some cancers, such as brain or breast cancers. Expression is dramatically increased in aggressive undifferentiated tumors, correlating with poor patient outcome in breast and brain cancers, suggesting a role in tumor-initiating cells and proliferation via its function in cell proliferation regulation. Function[MELK_HUMAN] Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis.[1] [2] [3] [4] [5] [6] References
|
|
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Non-specific serine/threonine protein kinase
- Beke, L.
- Berdini, V.
- Bonnet, P.
- Brehmer, D.
- Coyle, J E.
- Day, P J.
- Frederickson, M.
- Freyne, E J.E.
- Gilissen, R A.H J.
- Hamlett, C C.F.
- Howard, S.
- Johnson, C N.
- Linders, J T.M.
- McMenamin, R.
- Meerpoel, L.
- Patel, S.
- Rees, D C.
- Sharff, A.
- Sommen, F.
- Wu, T.
- Fragment sterbased drug design
- Kinase
- Transferase